Previous close | 4.9700 |
Open | 5.0500 |
Bid | 3.6100 x 200 |
Ask | 5.6900 x 200 |
Day's range | 4.4301 - 5.0700 |
52-week range | 2.1300 - 7.3700 |
Volume | |
Avg. volume | 69,950 |
Market cap | 300.725M |
Beta (5Y monthly) | 1.17 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.2200 |
Earnings date | 06 Aug 2024 - 12 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 8.67 |
SOPHiA GENETICS ( NASDAQ:SOPH ) First Quarter 2024 Results Key Financial Results Revenue: US$15.8m (up 13% from 1Q...
The average of price targets set by Wall Street analysts indicates a potential upside of 65% in SOPHiA GENETICS (SOPH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Consistent Operational Execution; Robust New Business Momentum; Guidance ReaffirmedBOSTON and ROLLE, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Highlights Revenue grew 13% year-over-year to $15.8 million; Constant currency revenue excluding COVID-related revenue grew 12% year-over-yearGross